Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
131,906,059
-
Number of holders
-
80
-
Total 13F shares, excl. options
-
36,211,271
-
Shares change
-
+264,490
-
Total reported value, excl. options
-
$47,075,130
-
Value change
-
+$6,613,804
-
Put/Call ratio
-
44%
-
Number of buys
-
42
-
Number of sells
-
36
-
Price
-
$1.30
Institutional Holders of Ovid Therapeutics Inc. - Common Stock, par value $0.001 per share (OVID) as of Q3 2025
As of 30 Sep 2025 Ovid Therapeutics Inc. - Common Stock, par value $0.001 per share (OVID) had 98 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 36,211,271 shares of stock of the company.
Largest 10 holders included TAKEDA PHARMACEUTICAL CO LTD, VANGUARD GROUP INC, Affinity Asset Advisors, LLC, ACADIAN ASSET MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, Sio Capital Management, LLC, Driehaus Capital Management LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., KENNEDY CAPITAL MANAGEMENT LLC, and Ikarian Capital, LLC.
This table shows 98 institutional shareholders of the security as of 30 Sep 2025.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.